Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.84 |
| ▸ | MAPT | P10636 | 8/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | TP53 | P04637 | 7/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20988891 | 0.88 | MAPT (0.79) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL28703726 | 0.84 | MAPT (0.93) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL20989297 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL20989296 | 0.84 | ALDH1A1 (0.78) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL28703720 | 0.81 | MAPT (0.93) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL20988941 | 0.81 | MAPT (0.69) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL20989215 | 0.81 | MAPT (0.66) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL4596903 | 0.80 | MAPT (0.75) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL28932883 | 0.80 | MAPT (1.00) | ALDH1A1MAPTHSD17B10NPSR1TP53 | |
| SCHEMBL28932882 | 0.78 | MAPT (0.89) | ALDH1A1MAPTHSD17B10NPSR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | KRAS, NRAS, HRAS | ALDH1A1 4716/4885MAPT 4750/4885HSD17B10 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.